BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31744552)

  • 1. A tricky and rare cause of pulmonary eosinophilia: myeloid/lymphoid neoplasm with eosinophilia and rearrangement of PDGFRA.
    Zanelli M; Smith M; Zizzo M; Carloni A; Valli R; De Marco L; Foroni M; Palicelli A; Martino G; Ascani S
    BMC Pulm Med; 2019 Nov; 19(1):216. PubMed ID: 31744552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
    Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates on eosinophilic disorders.
    Tzankov A; Reichard KK; Hasserjian RP; Arber DA; Orazi A; Wang SA
    Virchows Arch; 2023 Jan; 482(1):85-97. PubMed ID: 36068374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
    Gerds AT; Gotlib J; Bose P; Deininger MW; Dunbar A; Elshoury A; George TI; Gojo I; Gundabolu K; Hexner E; Hobbs G; Jain T; Jamieson C; Kuykendall AT; McMahon B; Mohan SR; Oehler V; Oh S; Pardanani A; Podoltsev N; Ranheim E; Rein L; Salit R; Snyder DS; Stein BL; Talpaz M; Thota S; Vachhani P; Wadleigh M; Walsh K; Ward DC; Bergman MA; Sundar H
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1248-1269. PubMed ID: 32886902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid Neoplasm with PDGFRA Rearrangement Manifesting as a Retromolar Pad Mass.
    Duffield AS; Webster J; Smith BD; Necciai JS; McCuiston A; Ware AD
    Head Neck Pathol; 2021 Dec; 15(4):1399-1403. PubMed ID: 33616851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma.
    Akiely R; Almasri F; Almasri N; Abu-Ghosh A
    Front Pediatr; 2022; 10():1059527. PubMed ID: 36589160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.
    Chaudhary LN; Bailey NG; Vos JA; Stotler CJ
    W V Med J; 2013; 109(2):6-9. PubMed ID: 23600098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilic myeloid neoplasms.
    Noel P; Mesa RA
    Curr Opin Hematol; 2013 Mar; 20(2):157-62. PubMed ID: 23385615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
    Rathe M; Kristensen TK; Møller MB; Carlsen NL
    Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.
    Hilal T; Fauble V; Ketterling RP; Kelemen K
    Cancer Genet; 2018 Jan; 220():13-18. PubMed ID: 29310833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary eosinophilic disorders: a concise review.
    Pardanani A; Tefferi A
    Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood and Bone Marrow Evaluation for Eosinophilia.
    Boyer DF
    Arch Pathol Lab Med; 2016 Oct; 140(10):1060-7. PubMed ID: 27684977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophilic myeloid disorders.
    Noel P
    Semin Hematol; 2012 Apr; 49(2):120-7. PubMed ID: 22449622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.